摘要
背景:遗传和表观遗传修饰与肿瘤的发生和发展密切相关,可为理解肿瘤的功能提供指导,并有可能导致迪斯科病毒的出现。新的治疗方法。研究表明,缺氧相关基因与脑肿瘤的进展和化疗/放射抵抗有关。缺氧相关基因在足叶甲中的表达谱研究髓母细胞瘤,虽然缺乏,但可能揭示相关的信息,可以支持治疗决定。 目的:研究41例新鲜冷冻髓母细胞瘤标本中CA9、CA 12、HIF1a、EPAS 1、SCL2A1和VEGF基因的表达。此外,我们还分析了低氧和低氧的影响。小儿髓母细胞瘤细胞株UW 402的D常氧。此外,我们还评估了HIF1a基因敲除对细胞增殖和与缺氧、凋亡相关基因甲基化水平的影响。和自噬。 方法:采用qPCR方法检测HIF1a基因的mRNA表达,Western blot检测HIF1a基因在细胞和细胞中的沉默。焦测序是用来评估甲基化水平的。R HIF1α在uw402细胞敲除。 结果:MB患者HIF1a mRNA水平高于小脑(非肿瘤匹配)。在uw 402 mb细胞中,化学诱导低氧可使mrna水平增加。HIF1a、VEGF、SCL2A1和CA9基因的LS。另外,HIF1a基因敲除可导致缺氧相关基因表达降低,细胞增殖也降低30%。也HIF1a基因敲除后,ATG16L1启动子甲基化明显增加,EPAS 1启动子甲基化降低。 结论:髓母细胞瘤细胞中HIF1a基因敲除导致细胞增殖减少,提示HIF1a是髓母细胞瘤治疗的潜在靶点。豪芙r.HIF1a蛋白稳定和功能的机制非常复杂,为了将HIF1a作为治疗靶点,需要更多的数据。
关键词: HIF1a,EPAS 1,髓母细胞瘤,表观遗传学,ATG16L1,缺氧。
图形摘要
Current Cancer Drug Targets
Title:HIF1A is Overexpressed in Medulloblastoma and its Inhibition Reduces Proliferation and Increases EPAS1 and ATG16L1 Methylation
Volume: 18 Issue: 3
关键词: HIF1a,EPAS 1,髓母细胞瘤,表观遗传学,ATG16L1,缺氧。
摘要: Background: Genetic and epigenetic modifications are closely related to tumor initiation and progression and can provide guidance for understanding tumor functioning, potentially leading to the discovery of new therapies. Studies have associated hypoxia-related genes to tumor progression and chemo/radioresistance in brain tumors. Information on the expression profile of hypoxiarelated genes in pediatric medulloblastoma, although scarce, may reveal relevant information that could support treatment decisions.
Objective: Our study focused on evaluation the of CA9, CA12, HIF1A, EPAS1, SCL2A1 and VEGF genes in 41 pediatric fresh-frozen medulloblastoma sample. Additionally, we analyzed the effect of hypoxia and normoxia in the pediatric medulloblastoma cell-line UW402. Furthermore, we assessed the effects of HIF1A knockdown in cell-proliferation and methylation levels of genes related to hypoxia, apoptosis and autophagy.
Method: qPCR was performed to evaluate mRNA levels, and Western blot to confirm HIF1A silencing in both patient samples and cell line. Pyrosequencing was performed to asses the methylation levels after HIF1A knockdown in the UW402 cell line.
Results: A higher HIF1A mRNA level was observed in MB patients when compared to the cerebellum (non-tumor match). In UW402 MB cell-line, chemically induced hypoxic resulted in an increase of mRNA levels of HIF1A, VEGF, SCL2A1 and CA9 genes. Additionally, HIF1A knockdown induced a decrease in the expression of hypoxia related genes and a decrease of 30% in cell proliferation was also observed. Also, a significant increase in the methylation of ATG16L1 promoter and decrease in the methylation of EPAS1 promoter were observed after HIF1A knockdown.
Conclusion: HIF1A knockdown in medulloblastoma cells lead to decreased cellular proliferation, suggesting that HIF1A can be a potential therapeutic target to be explored in the medulloblastoma. However, the mechanisms behind HIF1A protein stabilization and function are very complex and more data need to be generated to potentially use HIF1A as a therapeutical target.
Export Options
About this article
Cite this article as:
HIF1A is Overexpressed in Medulloblastoma and its Inhibition Reduces Proliferation and Increases EPAS1 and ATG16L1 Methylation, Current Cancer Drug Targets 2018; 18 (3) . https://dx.doi.org/10.2174/1568009617666170315162525
DOI https://dx.doi.org/10.2174/1568009617666170315162525 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Complex Obesity
Current Pediatric Reviews Theoretical Analysis for the Safe Form and Dosage of Amygdalin Product
Anti-Cancer Agents in Medicinal Chemistry DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents
Current Bioactive Compounds Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Emerging Technologies for Fertility Preservation in Female Patients
Current Women`s Health Reviews Busulfan Use in Hematopoietic Stem Cell Transplantation: Pharmacology, Dose Adjustment, Safety and Efficacy in Adults and Children
Current Drug Safety Recent Advances in the Prevention of Anthracycline Cardiotoxicity in Childhood
Current Medicinal Chemistry Host Pharmacogenetics in the Treatment of HIV and Cancer
Current Drug Safety Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Microbiome in Chronic Obstructive Pulmonary Disease: Role of Natural Products Against Microbial Pathogens
Current Medicinal Chemistry Subject Index To Volume 2
Current Hypertension Reviews Strategies for Developing Tuberculosis Vaccines: Emerging Approaches
Current Drug Targets Early Life Programming of Obesity: The Impact of the Perinatal Environment on the Development of Obesity and Metabolic Dysfunction in the Offspring.
Current Diabetes Reviews The Canalicular Bile Salt Export Pump BSEP (ABCB11) as a Potential Therapeutic Target
Current Drug Targets Stable Isotope Techniques to Develop and Monitor Nutrition Interventions
Current Nutrition & Food Science Could Targeting HMGB1 be Useful for the Clinical Management of COVID-19 Infection?
Combinatorial Chemistry & High Throughput Screening Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice
Current Pediatric Reviews OMICS-Derived Targets for Inflammatory Gut Disorders: Opportunities for the Development of Nutrition Related Biomarkers
Endocrine, Metabolic & Immune Disorders - Drug Targets PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights
Current Neuropharmacology